2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2022
Downregulation of hepatic ceruloplasmin ameliorates NAFLD via SCO1-AMPK-LKB1 complex
Xie L, Yuan Y, Xu S, Lu S, Gu J, Wang Y, Wang Y, Zhang X, Chen S, Li J, Lu J, Sun H, Hu R, Piao H, Wang W, Wang C, Wang J, Li N, White M, Han L, Jia W, Miao J, Liu J. Downregulation of hepatic ceruloplasmin ameliorates NAFLD via SCO1-AMPK-LKB1 complex. Cell Reports 2022, 41: 111498. PMID: 36261001, PMCID: PMC10153649, DOI: 10.1016/j.celrep.2022.111498.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLipid metabolism diseasesLipid catabolismHepatic lipid catabolismFatty acid oxidationDetectable hepatotoxicityCopper deficiencyNAFLD developmentLiver diseaseMetabolic diseasesMetabolism diseasesNormal levelsDiseaseMitochondrial biogenesisAcid oxidationAMPK activityAMPKAblationDeficiencyCatabolismLKB1Hepatotoxicity
2009
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity
Podoltsev N, Saif M. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity. Journal Of Clinical Oncology 2009, 27: e14588-e14588. DOI: 10.1200/jco.2009.27.15_suppl.e14588.Peer-Reviewed Original ResearchDeleterious mutationsCommon deleterious mutationSequence variationSequence analysisFull sequence analysisGenetic variantsMutationsFull sequencingDihydropyrimidine dehydrogenase gene polymorphismsDPYD mutationsGenetics laboratoriesSimple identificationDPYDDPYD geneGenesD949VSequencingDNAEnzymeToxicityIVS14CatabolismSequencePolymorphismBlood cells
1988
Human Keratinocytes Catabolize Thymidine
Schwartz P, Kugelman L, Coifman Y, Hough L, Milstone L. Human Keratinocytes Catabolize Thymidine. Journal Of Investigative Dermatology 1988, 90: 8-12. PMID: 3335793, DOI: 10.1111/1523-1747.ep12462412.Peer-Reviewed Original ResearchConceptsHuman keratinocytesHuman neonatal foreskinHuman neonatal foreskin keratinocytesNeonatal foreskin keratinocytesCutaneous diseaseSoluble extractsGuinea pigsNeonatal foreskinKeratinocyte proliferationForeskin keratinocytesStratified culturesRate of incorporationAdult skinRadioactive thymidineKeratinocytesThymidine analogueAmount of thymidineExogenous thymidineSpecies differencesThymidineHuman fibroblastsSkinCatabolismDifferent tissuesCulture medium
1978
Catabolism of 2-deoxyglucose by phagocytic leukocytes in the presence of 12-O-tetradecanoyl phorbol-13-acetate.
Zabos P, Kyner D, Mendelsohn N, Schreiber C, Waxman S, Christman J, Acs G. Catabolism of 2-deoxyglucose by phagocytic leukocytes in the presence of 12-O-tetradecanoyl phorbol-13-acetate. Proceedings Of The National Academy Of Sciences Of The United States Of America 1978, 75: 5422-5426. PMID: 310120, PMCID: PMC392976, DOI: 10.1073/pnas.75.11.5422.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply